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ABSTRACT 
Background and Purpose  
Intracerebral hemorrhage (ICH) volume, particularly if ≥30 mL, is a major determinant of poor 
outcome. We used a multinational ICH data registry to study the characteristics, course, and 
outcomes of supratentorial hematomas with volumes <30 mL.  
 
Methods 
Basic characteristics, clinical and radiological course, and 30-day outcomes of these patients 
were recorded. Outcomes were categorized as early neurological deterioration (END), hematoma 
expansion, Glasgow Outcome Scale (GOS), and in-hospital death. Poor outcome was defined as 
composite of in-hospital death and severe disability (GOS ≤3). Comparison was conducted based 
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on hemorrhage location. Logistic regression using dichotomized outcome scales was applied to 
determine predictors of poor outcome. 
 
Results 
Among 375 cases of supratentorial ICH with volumes <30 mL, expansion and END rates were 
19.2% and 7.5%, respectively. Hemorrhage growth was independently associated with END 
(odds ratio: 28.7, 95% confidence interval [CI]: 8.51–96.5; p<0.0001). Expansion rates did not 
differ according to ICH location. Overall, 13.9% (exact binomial 95% CI: 10.5–17.8) died in the 
hospital and 29.1% (CI: 24.5–34.0) had severe disability at 30 days; a cumulative poor outcome 
rate of 42.9% (CI: 37.9–48.1).  Age, admission Glasgow Coma Scale, intraventricular extension, 
and END were independently associated with poor outcome. There was no difference in poor 
outcome rates between lobar and deep locations (40.2% versus 43.8%, p=0.56).  
 
Conclusion 
Patients with supratentorial ICH <30 mL have high rates of poor outcome at 30 days, regardless 
of location. Nearly one in five hematomas <30 mL expands, leading to END or death.  
 
 
INTRODUCTION   
Intracerebral hemorrhage (ICH) is the most pernicious form of stroke, wherein approximately 
1/3 of patients die within the first 30 days [1]. Several characteristics independently predict early 
death and poor functional outcome in ICH patients [2,3]. Initial ICH volume and hematoma 
enlargement are among the strongest determinants of mortality and disability [4,5]. As such, 
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attenuation of hematoma expansion has been the objective of many interventional clinical trials 
in ICH and remains a tantalizing therapeutic target. It is unclear, however, whether this strategy 
has a beneficial effect on outcomes notwithstanding ICH size. Very large hemorrhages 
inherently have less favorable outcomes. The rates of mortality and poor outcome especially 
increase when ICH volume exceeds 30 mL [2-4]. This cut-off is used as a prognostic item in 
estimation of the ICH Score [2,3]. Although outcomes in patients with the initial ICH volume 
≥30 mL have been adequately delineated in various studies, less is known about supratentorial 
ICH <30 mL. The aim of this study was to determine the characteristics, clinical course, and 
outcomes of patients with small (<30 mL) supratentorial hematomas. 
 
METHODS  
Study Design  
A cohort design was applied, wherein ICH occurrence defined the qualifying event. We used the 
Multi-National survey of Epidemiology, Morbidity, and Outcomes iN Intra-Cerebral 
Haemorrhage (MNEMONICH) registry to compile the data for this study. MNEMONICH 
(NCT2567162 ClinicalTrials.gov) is an ongoing, international, multicenter, observational, 
collaborative database of consecutive adult (≥18 years of age) patients with spontaneous ICH 
from participating centers in Europe, Latin America, and the United States [6,7]. It consists of 
existing and ongoing datasets from international collaborators who have agreed to a mutual peer-
to-peer exchange of collected data on spontaneous ICH patients aged ≥18 years. Approval by the 
each center’s ethics committed or review board was obtained. Data compilation and retention are 
based on informed consent provided by patients or their legal representatives. Information from 
various databases are anonymized and recorded in a unique format before inclusion in the 
registry. Registered data include demographics, clinical, laboratory, anatomic/histo-pathological, 
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and neuro-radiological findings collected at the participating centers. Quality control and 
consistency of methodology and data, such as agreement on computed tomography (CT) scan 
interpretation between participating institutions are monitored and checked regularly by the 
coordinating center in Rieti, Italy. Any inconsistency is discussed and resolved with agreement. 
Data of interest included age, sex, ICH volume, ICH location (thalamus, basal ganglia/internal 
capsule, and lobar), intraventricular hemorrhage (IVH), Graeb Score (if IVH present), initial 
Glasgow Coma Scale (GCS) scores, initial International Normalisation Ratio (INR), 30-day 
outcomes based on Glasgow Outcome Scale (GOS) scores, and prior antiplatelet agent and 
anticoagulant use.  
 
Case Ascertainment     
We specifically extracted data on patients who presented with supratentorial ICH <30 mL in 
volume. Patients with anticoagulant-associated ICH are also included. To prevent any potential 
confounding effects, patients who had undergone surgical evacuation were excluded.  
 
Neuroimaging  
In MNEMONICH, spontaneous ICH is defined as acute intraparenchymal bleeding confirmed by 
CT scan, in the absence of secondary etiology (e.g. brain tumors/infections, vascular 
malformations, aneurysms, hemorrhagic transformation of cerebral infarcts, and trauma). ICH 
volume was calculated using the ABC/2 method [8]. No data on CT angiography or specifically 
the “spot sign” were collected.  
 
Outcome Determination  
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We gathered data on early neurological deterioration (END) and ICH expansion. END was 
defined as ≥3 points decrease in the GCS score for non-comatose patients (GCS >8) or ≥2 point 
decrease for comatose patients (GCS ≤8), presence of a new neurological deficit or worsening of 
previous deficit, or the appearance of clinical signs of brain herniation within 24 hours of 
admission [9]. ICH expansion was defined as any increase in the original hematoma volume by 
33% or more.    
 
Statistical Methods  
We divided ICH cases into 3 categories based on location: thalamus, basal ganglia/internal 
capsule (including the caudate nucleus), and lobar. Data were presented as mean ± standard 
deviation for normally distributed continuous variables, median and interquartile range for non-
normally distributed continuous variables, and as frequencies for categorical variables. Baseline 
characteristics between patient groups were compared using χ2-test, ANOVA, and Kruskal-
Wallis test, as appropriate. Multiple comparisons were conducted using Marascuillo's post hoc 
procedure for proportions, ANOVA with Bonferroni corrections for normally distributed 
variables, and Kruskal-Wallis test with Dunn-Bonferroni post hoc method for non-normally 
distributed variables. We further divided the cases into volume tertiles, <10 mL, 10-20 mL, and 
>20 mL, and used with Marascuillo's post hoc analysis following comparing multiple 
proportions to compare hematoma expansion rates of each volume tertile according to location.    
 
The primary outcomes was the composite endpoint of severe disability (defined as GOS ≤3) and 
30-day mortality. To determine whether ICH location or other known ICH prognostic factors 
were associated with the primary outcome, multivariable logistic regression was performed. In 
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this model, we adjusted for prespecified baseline characteristics known potentially to influence 
survival and outcomes in ICH: gender, IVH, END, INR >1.4 on admission were included as 
binary variables; age, baseline ICH volume (log transformed), serum glucose at admission, and 
GCS score were treated as continuous variables. Goodness of the model for assessment of 
multivariate collinearity was tested using the variance inflation factor with exclusion in the final 
model of collinear variables. We reported the results as unadjusted and adjusted odds ratios (OR) 
with 95% confidence intervals (CI). Statistical significance for all analyses was set at 
p<0.05. Statistical analyses were performed using SPSS® 22.0 (IBM® Inc.). 
 
RESULTS   
Baseline Characteristics   
Among 716 ICH patients included in the registry, there were 375 (52.4%) cases of supratentorial 
ICH with volumes <30 mL. The mean age for this group was 67.1 ±12.3 years and 63.7% were 
men.  Table 1 compares the baseline characteristics of the study cohort according to specific 
hematoma location (Supplementary Table I compares deep [thalamus plus basal ganglia/internal 
capsule] versus lobar). Overall, compared with other ICH locations, patients with thalamic ICH 
presented with higher mean systolic blood pressure, had significantly higher prevalence of 
hypertension, and a higher rate of IVH. Furthermore, thalamic ICH cases with IVH had higher 
median Graeb scores than lobar and basal ganglia/internal capsule hematomas with 
intraventricular extension. However, median initial hematoma volume was lowest in patients 
with thalamic ICH and highest in the lobar group. Thalamic ICH patients also presented with 
higher median GCS score than the rest of the cohort (basal ganglia/internal capsule patients had 
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the lowest).  Lobar ICH patients were more likely to be on oral anticoagulants than the remainder 
of the cohort, but the proportion of patients with INR >1.4 in each group was not different.    
 
Clinical Course  
Hematoma expansion and END rates for the total cohort were 19.2% (9.2% had missing data) 
and 7.5%, respectively. The rates and measure of expansion and END did not differ between the 
three locations (Table 2) or deep versus lobar (Supplementary Table II). After adjusting for age, 
gender, baseline ICH volume (log transformed), admission GCS, IVH, and initial INR >1.4, 
hematoma expansion was strongly associated with END (OR: 28.7, 95% CI: 8.51 – 96.5; 
p<0.0001). Within each volume tertile, the rates of ICH growth were not different when stratified 
according to specific hematoma location (Table 3). However, in the lobar and basal 
ganglia/internal capsule groups, ICH volume categories 1–9 mL showed significantly higher 
rates of expansion than volumes >9 mL (Table 3). No significant difference between volume 
tertiles was noted in the rates of thalamic hematoma expansion.   
 
Outcomes  
Fifty-two patients (13.9%) died in the hospital, and 109 (29.1%) had a severe disability (GOS 
scores, 3 and 2) at 30 days. The overall rate of poor outcome (GOS ≤3) was 42.9%.  We found 
no difference between the three ICH location in the rates of in-hospital death, severe disability at 
30 days, or poor outcome (Table 2).  ICH location was also not a predictor of outcome in either 
univariate or multivariate analysis. Specifically, there was no difference in the rates of poor 
outcome between lobar versus deep locations (40.2% versus 43.8%; p = 0.56) (Supplementary 
Table III). In the univariate model, age, admission GCS, initial volume, IVH, END, and INR 
Page 8 of 21
9 
 
>1.4 were associated with poor outcome (Table 4). Initial serum glucose had a modest but 
statistically significant predictive power. However, in multiple logistic regression analysis, only 
age (OR: 1.04, 95% CI: 1.03-1.08; p<0.0001), admission GCS (OR: 0.68, 95% CI: 0.59-0.79; 
p<0.0001), IVH (OR: 2.63, 95% CI: 1.28-4.42; p=0.008), and END (OR: 8.1, 95% CI: 2.55-
25.78; p<0.0001) remained associated with the poor outcome (Table 4).  
 
DISCUSSION  
This study demonstrated that supratentorial hematomas that are <30 mL in volume comprise a 
large proportion of patients with ICH. Within this category, 42.9% died in the hospital or were 
left with severe disability at 30 days. Although this figure may be lower than the overall 
estimated rate of poor outcome for ICH, it highlights the fact that even smaller-volume 
supratentorial hematomas can expand and have devastating outcomes. A recent study looking at 
315 ICH patients stratified by ICH volume showed that the rates of >33% expansion in volume 
categories of 3–10 mL and 10–20 mL were 26% and 32.9%, respectively [10]. At 90 days, in 
patients with ICH volumes 3–20 mL, the rate of poor outcome (modified Rankin Scale score ≥4) 
was 41.9%, which is very close to our number. In our study, expansion was independently 
associated with END and ultimately, poor outcome. Moreover, we found that known 
determinants of mortality and poor outcome (age, initial GCS score, ICH volume, and IVH) 
appropriately apply to this subset of ICH patients [2,3].  
  
One of the earliest studies looking at the significance of ICH volume in predicting outcomes 
showed that the overall 30-day mortality rates for ICH volumes <30 mL was 23% for deep and 
7% for lobar hemorrhages [4]. A combination of hematoma volume and the initial GCS score 
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was a strong predictor of 30-day morbidity and mortality. The probabilities of death by 30 days 
with ICH volume <30 mL and initial GCS score ≥9 and ≤8 were 19% and 44%, respectively [4]. 
Our study, too, showed that GCS score on presentation was a strong predictor of outcome. While 
prior studies have shown initial ICH volume as an independent determinant of GCS score on 
presentation, we found low GCS to be a powerful predictor of poor outcome even in patients 
with smaller-volume hematomas [11].  
 
Another important finding in our study was that in hematomas <30 mL, specific ICH locations 
were not major determinants of mortality or outcome. Lobar hemorrhages were, on average, 
larger in volume in our study, which is consistent with prior reports [12]. However, the 
prognostication capacity of deep localisation may be volume-dependent, consummating at 
volumes above 30 mL, where deep hematomas have worse outcomes than lobar hemorrhages but 
not for volumes below 30 mL [13]. In addition, the mortality rate in patients with thalamic 
hemorrhages was similar to that of patient with basal ganglia/internal capsule hematomas, 
contrary to previous investigations, suggesting that the prognostication capacity of different deep 
localisation is prevalently volume-dependent [14-16]. 
 
Surgical evacuation of deeply situated hematomas with volumes <30 mL, even with minimally 
invasive techniques, does not seem to carry a substantial benefit, regardless of the initial GCS 
score [17,18]. In a study of 400 patients with spontaneous putaminal and thalamic hemorrhages 
who underwent conservative treatment versus surgical evacuation (including endoscopic and 
stereotactic aspiration), mortality rates were lower for the conservative management group, 
compared with surgical treatment when the GCS score was 3 to 12 and ICH volume <30 mL 
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[18]. Currently, minimally invasive hematoma evacuation strategies under investigation only 
include patients with ICH volume ≥30 mL, consequently leaving a treatment gap for hematomas 
with smaller volume [19]. This subgroup of ICH patients may therefore, be suitable candidates 
for hemostatic therapy, which requires examination in a randomized trial.  
 
Our study had several important limitations. There was probably no uniformity among the 
patients in terms of door-to-CT times. Also, information on onset-to-CT time was not available 
on many patients and as a result, a figure representative of all ICH cases could not be stipulated.  
These factors may have interfered with estimating the rates of expansion since delayed imaging 
may have diagnosed ICH at a time when the hematoma had reached maximal expansion. 
Nonetheless, this is probably a more accurate representative of real-world stroke care. For 
expansion analysis, we only included data on patients who had follow-up CT, resulting in a 9.2% 
attrition. This may have also lead to preclusion from analyses of a number of patients who had 
ICH expansion, but without clinical sequelae, thus eliminating the necessity for repeat imaging.  
 
In conclusion, we demonstrated that more than one-third of patients with supratentorial ICH <30 
mL in volume die or are severely disabled by 30 days. One in every five supratentorial 
hematomas of this size category expand. Small thalamic and basal ganglia/internal capsule 
hemorrhages are a group of supratentorial ICH with similar clinical prognosis. Treatment of 
smaller-sized hematomas via interventional strategies, particularly hemostatic therapy, should be 
entertained as a potential focus area for future cerebrovascular research.  
 
The authors declare no conflict of interest.  
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Table 1 - Baseline characteristics stratified by location  
 Thalamus 
N = 124 
Basal 
Ganglia/Internal 
capsule 
N = 164 
Lobar 
N = 87 
p 
Men
*
  79 (63.7%) 110 (67.1%) 49 (56.3%) 0.4 
Mean Age (years)
†
 ±SD 67.1 ±12.3 65.2 ±13.1 67.8 ±13.2 0.3 
History of Hypertension
*
 105 (84.7%)
a,b
 107 (65.2%)
b
 50 (58.1%)
a
 <0.0001 
History of Diabetes Mellitus
*
 34 (27.4%)  38 (23.2%) 14 (16.1%) 0.2 
OAT Use
* 2 (1.6%)  9 (5.5%) 8 (9.2%) 0.05 
APA Use
* 35 (28.2%) 33 (20.1%) 16 (18.4%) 0.2 
Mean Admission SBP (mmHg)
†
 ±SD 180 ± 30
b,c
 178 ± 29
c
 164 ± 29
b
 0.006 
Median Admission GCS
‡ 
(IQR) 12 (10-14)
a,c
 11 (10-13)
a
 12 (7-13)
c
 0.001 
Median Admission ICH score
‡
 (IQR) 2 (1-2)
a,a
 2 (1-3)
a
 2 (1-3)
a
 <0.0001 
Median Initial Hematoma Volume
‡
 (IQR) 10 (8-15)
b,c
 11 (6-20)
c
 19 (16-24)
b
 0.001 
IVH
*
   67 (54%)
a,b
 31 (18.9%)
a
 13 (14.9%)
b
 <0.0001 
Median Graeb score
‡
 (IQR) 4 (3-6)
c
 4 (3-6) 2 (2-4)
c
 0.04 
Page 16 of 21
17 
 
Median Admission INR
‡
 (IQR) 1.15 (1.10-1.22) 1.12 (1.10-1.18) 1.11 (1.0-1.6) 0.6 
INR >1.4
*
 15 (12.1%) 14 (8.5%) 15 (17.2%) 0.1 
Mean Admission Platelet Count (cell x 10
9
/L)
†
 ±SD 239 ±54 253 ±66 238 ±81 0.2 
Mean Admission Serum Glucose (mg/dL)
†
 ±SD 159 ±53
c
 140 ±53 132 ±64
c
 0.01 
SD depicts standard deviation; OAT, oral anticoagulant therapy; APA, antiplatelet agent; IQR, interquartile range; IVH, 
intraventricular hemorrhage; INR, International Normalization Ratio. 
*χ2-test with Marascuillo's post hoc analysis following comparing multiple proportions.  
†
ANOVA test with Bonferroni corrections for multiple
 
comparisons. 
‡
Kruskal-Wallis test with Dunn-Bonferroni post hoc method for multiple
 
comparisons. 
Significant differences between subgroups are indicated in the table with APA-style formatting using subscript letters. 
a
p<0.0001; 
b
p<0.001; 
c
p<0.05  
 
 
  
Page 17 of 21
18 
 
Table 2 - Outcomes stratified by location  
 Thalamus 
N = 124 
Basal 
Ganglia/Internal 
capsule 
N = 164 
Lobar 
N = 87 
p 
Number of Expansions 26 (24.8%)   32 (20.9%) 14 (17.3%) 0.5 
Median Absolute Expansion (mL) (IQR) 0 (0-3) 2 (0-6.1) 0.5 (0-5) 0.7 
Median Expansion (%) (IQR) 0 (0-20) 22.5 (0-70) 2.1 (0-50) 0.7 
END 8 (6.5%)  13 (7.3%) 7 (8.0%) 0.9 
In-Hospital Death 24 (19.4%)  17 (10.4%) 11 (12.6%) 0.09 
Severe Disability at 30 Days 34 (27.4%)  52 (31.1%) 24 (27.6%) 0.3 
Median Time from CT1 to CT2 (hours) (IQR)  20 (12-24) 22.5 (17-24) 18 (16-21) 0.4 
Severe Disability and Death Composite (Poor Outcome)  58 (46.8%) 68 (42.2%) 35 (40.2%) 0.6 
IQR, interquartile range; END, early neurological deterioration; CT1, initial head computed tomography; CT2; follow up head 
computed tomography.  
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Table 3 - Expansion rates based on hematoma location and volume 
 Total  
N=339 
Expansion 
N=72 
Thalamus  
N=105 
Basal 
Ganglia/Internal 
Capsule N= 153 
Lobar  
N=81 
p* 
1 – 9 mL, n (%) 128 
 
40 16 / 40 
(40.0) 
16 / 33
c
 
(48.5) 
8 / 15
c
 
(53.3) 
0.8 
10 – 20 mL, n (%) 148 26 8 / 31 
(25.8) 
13 / 59 
(22.0) 
5 / 32 
(15.6) 
0.7 
>20 mL, n (%) 63 6 2 / 8 
(25.0) 
3 / 29
c
 
(10.3) 
1 / 20
c
 
(0.05) 
0.4 
p*   0.6 0.03  0.02  
*χ2-test with Marascuillo's post hoc analysis following comparing multiple proportions.  
Significant differences between subgroups are indicated in the table with APA-style formatting using subscript letters. 
a
p<0.0001; 
b
p<0.001; 
c
p<0.05  
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Table 4. Univariate and Multiple Logistic Regression Analysis for Composite of Severe Disability and Death at 30 Days  
 OR 95% CI  P 
UNIVARIATE 
Male Sex 1.32 0.86-2.02 0.2 
Age (per 1-year increase) 1.05 1.03-1.07 <0.0001 
GCS 0.72 0.65-0.80 <0.0001 
Thalamus 1.31 0.75-2.27 0.3 
Basal Ganglia/Internal Capsule 1.05 0.62-1.79 0.9 
Lobar 1.0 - - 
IVH 3.43 2.16-5.46 <0.0001 
Admission Glucose (per 1 mg/dL increase) 1.005 1.001-1.008 0.02 
END 4.44 1.84-10.71 <0.0001 
Initial Volume* 1.32 1.02-1.69 0.03 
INR > 1.4  2.10 1.11-3.98 0.02 
MULTIVARIATE 
Male Sex 1.88 0.94 – 3.78 0.08 
Age 1.05 1.03 – 1.08  < 0.0001 
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GCS 0.68 0.59 – 0.79 <0.0001 
Thalamus 1.16 0.46-2.96 0.2 
Basal Ganglia/Internal 
Capsule 
1.41 0.62-3.23 0.4 
Lobar 1.0 - - 
IVH 2.63 1.28 – 4.42 0.008 
Admission Glucose 1.00 0.99 – 1.00 0.4 
END 8.1 2.55 – 25.78 <0.0001 
Initial Volume* 1.55 0.88 – 2.72 0.1 
INR > 1.4  1.62 0.62 – 4.27 0.3 
OR, odds ratio; CI, confidence interval; GCS, Glasgow Coma Scale; IVH, intraventricular hemorrhage; END, early neurological 
deterioration; INR, International Normalization Ratio.  
*Log transformed 
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